tradingkey.logo
tradingkey.logo
Search

Transcode Therapeutics Inc

RNAZ
Add to Watchlist
4.750USD
-0.500-9.52%
Close 07-31 16:00ETQuotes delayed by 15 min
3.96MMarket Cap
LossP/E TTM

Transcode Therapeutics Inc

4.750
-0.500-9.52%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-9.52%

5 Days

-19.90%

1 Month

-23.51%

6 Months

-49.95%

Year to Date

-30.45%

1 Year

-57.21%

Key Figures
5.130Open
5.370High
30.26KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
3.63%Turnover Ratio
5.250Prev. Close
4.470Low
69.04KTurnover
LossP/E Static
2.78P/B
0.00%Div Yield TTM
-47.38%ROA
20.99052wk High
1.42Volume Ratio
-16.82MNet Profit
833.68KShares
-3.7086EPS TTM
1.32Beta
-757.04%ROE
5.01052wk Low
17.14%Amplitude
--Gross Margin
3.96MMarket Cap
-6.35Reward/Risk
6.14%Risk Rate

Transcode Therapeutics Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 0 analysts
--
Current Rating
10.000
Target Price
+2266.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Transcode Therapeutics Inc
RNAZ
0
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99

Indicators

Indicators
Sell(2)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.949
Neutral
RSI(14)
33.579
Neutral
STOCH(KDJ)(9,3,3)
7.380
Oversold
ATR(14)
0.789
High Vlolatility
CCI(14)
-102.251
Sell
Williams %R
98.173
Oversold
TRIX(12,20)
-0.370
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
5.044
Sell
MA10
6.355
Sell
MA20
7.430
Sell
MA50
6.296
Sell
MA100
7.342
Sell
MA200
8.496
Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Transcode Therapeutics Inc Info

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Ticker SymbolRNAZ
CompanyTranscode Therapeutics Inc
CEOCalais (Philippe P)
Websitehttps://www.transcodetherapeutics.com/

Shareholders

Shareholders
Shareholders
Proportion
CK Life Sciences International Holdings, Inc.
9.08%
Sabby Management, LLC
4.54%
Geode Capital Management, L.L.C.
1.20%
UBS Financial Services, Inc.
0.90%
Vanguard Capital Management, LLC
0.71%
Other
83.57%

FAQs

What is the current price of Transcode Therapeutics Inc (RNAZ)?

The current price of Transcode Therapeutics Inc (RNAZ) is 4.75.

What is the symbol of Transcode Therapeutics Inc?

The ticker symbol of Transcode Therapeutics Inc is RNAZ.

What is the 52-week high of Transcode Therapeutics Inc?

The 52-week high of Transcode Therapeutics Inc is 20.99.

What is the 52-week low of Transcode Therapeutics Inc?

The 52-week low of Transcode Therapeutics Inc is 5.01.

What is the market capitalization of Transcode Therapeutics Inc?

The market capitalization of Transcode Therapeutics Inc is 3.96M.

What is the Earnings Per Share (EPS TTM) of Transcode Therapeutics Inc (RNAZ)?

The Earnings Per Share (EPS TTM) of Transcode Therapeutics Inc (RNAZ) is -52.59.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.